<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436955</url>
  </required_header>
  <id_info>
    <org_study_id>BP25543</org_study_id>
    <nct_id>NCT01436955</nct_id>
  </id_info>
  <brief_title>A Study of RG1662 in Individuals With Down Syndrome</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Investigate Safety and Tolerability of RG1662 in Individuals With Down Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multi-center, randomized double-blind, placebo-controlled study will assess the safety&#xD;
      and tolerability of RG1662 in individuals with Down Syndrome. Eligible subjects will be&#xD;
      randomized in cohorts to receive either multiple oral doses of RG1662 or placebo. Anticipated&#xD;
      time on study treatment is 38 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive assessment: CANTAB (Computerized battery for assessing motor practice, reaction time and memory)/standard cognitive tests</measure>
    <time_frame>5-6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Serum concentration/area under the concentration-time curve (AUC)</measure>
    <time_frame>5-6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Down Syndrome</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RG1662</intervention_name>
    <description>Cohorts receiving multiple oral doses</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult individuals, 18 to 30 years of age, with diagnosis of Down Syndrome (confirmed&#xD;
             by karyotype)&#xD;
&#xD;
          -  Males and non-pregnant non-lactating females&#xD;
&#xD;
          -  Parent or legal guardian/representative and caregiver willing to give written informed&#xD;
             consent&#xD;
&#xD;
          -  Subject willing and assenting or consenting to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major depressive disorder not adequately controlled by a selective serotonin reuptake&#xD;
             inhibitor or a serotonin norepinephrine reuptake inhibitor&#xD;
&#xD;
          -  Subjects meeting clinical diagnostic criteria for autistic spectrum disorder,&#xD;
             attention deficit or hyperactivity disorder unlikely to cooperate and take part&#xD;
             successfully in the study assessments&#xD;
&#xD;
          -  Subjects with other primary psychiatric diagnosis&#xD;
&#xD;
          -  Subjects with evidence or meeting clinical diagnosis of dementia&#xD;
&#xD;
          -  Subjects with personal history of cardiac abnormalities; patients that have previously&#xD;
             undergone congenital heart surgery can be enrolled provided they have no residual&#xD;
             complication requiring intervention (e.g. pace maker)&#xD;
&#xD;
          -  Subjects with clinically significant obstructive pulmonary disease or asthma that is&#xD;
             not adequately treated (oral steroids are not allowed)&#xD;
&#xD;
          -  Subjects with thyroid dysfunction that is not adequately controlled and stabilized on&#xD;
             treatment for at least 8 weeks&#xD;
&#xD;
          -  Subjects with sustained elevated supine blood pressure (SBP/DBP) at rest exceeding&#xD;
             140/90 mmHg or notable resting tachycardia (mean HR &gt; 60 bpm) or blood pressure below&#xD;
             90/40 mmHg&#xD;
&#xD;
          -  Subjects who have taken any other investigational medications within 3 months&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 40 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <last_update_submitted>March 2, 2015</last_update_submitted>
  <last_update_submitted_qc>March 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

